Global Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients
|
|
- Anthony Fletcher
- 5 years ago
- Views:
Transcription
1 Research Article Global Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients Cancer Epidemiology, Biomarkers & Prevention Bo-lin Liu 1, Jin-xiang Cheng 1, Xiang Zhang 1, Rui Wang 2, Wei Zhang 1, Hong Lin 1, Xian Xiao 1, Sang Cai 1, Xiao-yan Chen 1,3, and Hong Cheng 3 Abstract Background: An altered pattern of epigenetic modifications is central to the development and progression of various tumors. We studied epigenetic changes involving multiple modifications of histones to better predict prognosis of glioma patients. Methods: Immunohistochemistry was done to investigate global histone modification expression of histone 3 lysine 4 dimethylation (H3K4diMe), histone 4 arginine 3 monomethylation (H4R3monoMe), histone 4 lysine 20 trimethylation (H4K20triMe), and acetylation of histone 3 lysine 9 (H3K9Ac), histone 3 lysine 18 (H3K18Ac), histone 4 lysine 12 (H4K12Ac), and histone 4 lysine 16 (H4K16Ac) in resected tumor samples of 230 glioma patients. Data were analyzed using a recursive partitioning analysis (RPA). Results: RPA classified the patients into 10 distinct prognostic groups based on WHO grade, histology, and histone modifications: H3K9Ac (<88% or 88% tumor cells), H3K4diMe (<64% or 64% tumor cells), H3K18Ac (<74% or 74% tumor cells), and H4K20triMe (<75% or 75% tumor cells). The 10 groups were associated with significantly different progression-free (P < ) and overall survival (P < ). Cox proportional hazards models including age, sex, WHO grade, histology, extent of tumor resection, Karnofsky performance status score, and RPA groups retained age and RPA groups as the sole independent factors significantly influencing overall survival. For progression-free survival, RPA grouping was the only independent prognostic factor. Conclusions: Multiple histone modifications seem to have prognostic relevance in glioma. Impact: Further evaluation of histone modifications as prognostic markers of treatment and predictors of chemotherapy response using histone deacetylase inhibitors is warranted. Cancer Epidemiol Biomarkers Prev; 19(11); AACR. Introduction Approximately 22,500 new cases of primary brain tumors occur annually in the United States, accounting for 1.4% of all tumors and 2.3% of cancer-related deaths (1). Glioma represents >70% of all brain tumors, including low-grade glioma (WHO grade 1 and 2) and highgrade glioma (WHO grade 3 and 4; refs. 2, 3). Despite recent advances in surgery, radiotherapy, and chemotherapy, survival of glioma patients remains poor. The 5-year survival rates of low-grade glioma are 30% to 70% depending on histology (4), and the median survival Authors' Affiliations: 1 Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing Hospital and Departments of 2 Health Statistics and 3 Pathology, Fourth Military Medical University, Xi'an, Shaanxi Province, People's Republic of China Note: B. Liu and J. Cheng contributed equally to this work. Corresponding Author: Xiang Zhang, Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing Hospital, Fourth Military Medical University, West Changle Road, No. 127, Xi'an, Shaanxi Province , People's Republic of China. Phone: ; Fax: xzhang@fmmu.edu.cn doi: / EPI American Association for Cancer is only 12 to 15 months for the most frequent and malignant glioblastoma (5). Although WHO grade is the most important prognostic factor for glioma patients, there are broad differences within grades, which may be caused by different tumor-specific biological behavior (5, 6). Thus, the identification of biomarkers might help to assess more precisely the prognosis and to address more clearly the use of adjuvant therapy. Besides genetic alterations, epigenetic modifications are critical to the development and progression of cancer (7). Epigenetics was defined as heritable changes in gene expression that are not a result of any alteration in the DNA sequence (8), whose mechanisms include but are not limited to aberrant DNA methylation, histone modification, and micrornas. The best-known epigenetic marker is DNA methylation. Hypermethylation of the CpG island promoter can induce silencing of genes affecting the cell cycle, DNA repair, metabolism of carcinogens, cell-to-cell interaction, apoptosis, and angiogenesis, all of which may occur at different stages in cancer development and interact with genetic lesions (9, 10). In addition to DNA promoter hypermethylation, global alterations of histone modification patterns have the potential to affect the structure and integrity of the 2888 Cancer Epidemiol Biomarkers Prev; 19(11) November 2010
2 Histone Modifications Predict Glioma Prognosis genome and to disrupt normal patterns of gene expression, which may also contribute to carcinogenesis (9, 11). These modifications occur in different histone proteins, histone variants, and histone residues; involve different chemical groups; and have different degrees of methylation (11). Recently, the global pattern of histone modification was identified by different study groups as a predictor of the risk of recurrence in prostate cancer patients (12), a predictor of prognosis in non smallcelllungcancer patients (13), and a predictor of both the recurrence of cancer and independent prognostic factor in gastric adenocarcinoma patients (14). We studied the pattern of global histone modification as a potential prognostic marker in resected glioma tissues. Immunohistochemistry was done to evaluate the global histone modification expression level of histone 3 lysine 4 dimethylation (H3K4diMe), histone 4 arginine 3 monomethylation (H4R3monoMe), histone 4 lysine 20 trimethylation (H4K20triMe), and acetylation of histone 3 lysine 9 (H3K9Ac), histone 3 lysine 18 (H3K18Ac), histone 4 lysine 12 (H4K12Ac), and histone 4 lysine 16 (H4K16Ac; refs. 12, 15). The relationship between multiple histone modifications and patient prognosis was analyzed by a recursive partitioning analysis (RPA), with overall survival (OS) as the primary end point. Materials and Methods Patients Patients hospitalized at the Department of Neurosurgery of Xijing Hospital (Xi'an, People's Republic of China) between January 2003 and December 2007 were included in our study if they met the following criteria: (a) age older than 14 years, (b) with pathologically confirmed glioma (WHO grades 1-4), (c) underwent radical neurosurgery of primary tumor, (d) without other cancer or fatal diseases, (e) not lost to follow-up, and (f) informed consent was obtained. Eligible glioblastoma patients received stereotactic fractionated radiosurgery to a median total dose of 55 Gy and a median of three courses of i.v. carmustine (100 mg/m 2 ) given at 4-week intervals postoperatively; eligible patients with WHO grade 3 tumors (anaplastic astrocytoma, anaplastic oligoastrocytoma, and anaplastic oligodendroglioma) received stereotactic fractionated radiosurgery to a median total dose of 36 Gy postoperatively. Major clinical and biological characteristics of the qualified 230 patients are summarized in Table 1. The histopathologic features and WHO grade of the tumor specimens were determined according to the WHO 2007 classification (3). Local institutional review board approval was obtained to use archived material for research purposes. Immunohistochemistry Immunohistochemistry was done as previously described (13). Briefly, specific rabbit polyclonal antibodies were used to detect global expression of seven different histone modifications, including H3K4diMe, H4R3- monome, H4K20triMe, H3K9Ac, H3K18Ac, H4K12Ac, and H4K16Ac (Abcam), using standard two-step indirect immunohistochemical staining method. Following deparaffinization, rehydration, quench of endogenous peroxidase, antigen retrieval, and blockage of nonspecific protein binding, primary antibodies were applied overnight as follows: H3K4diMe, 1:200; H4R3- monome, 1:100; H4K20triMe, 1:400; H3K9Ac, 1:100; H3K18Ac, 1:200; H4K12Ac, 1:150; H4K16Ac,1:100. Detection was accomplished using the DAKO Envision System, followed by chromogen detection with diaminobenzidine, and then counterstaining with Harris' hematoxylin, dehydration, and mounting. Negative controls were identical whole-tissue section stained without the primary antibody. A semiquantitative assessment was done independently by two observers (B.L. and S.C.) blinded to the clinicopathologic information. Either intermediate or strong nuclear staining was considered positive, and, regardless of the staining intensity, the score of each whole-tissue section was based on the proportion of positive tumor cells (range, 0-100%); the score of each sample was the mean value of three continuous whole-tissue sections per antibody. Statistical analysis Follow-up data were updated in February The OS was calculated from the date of surgery to date of death as a result of any cause. Progression-free survival (PFS) was calculated from the date of surgery to date of documented tumor recurrence or further growth of residual tumor or death from any cause. Patients who were alive at the date of the last follow-up were censored on that date plus 1 day. Probability of survival was estimated using the Kaplan-Meier method. Differences in survival were tested by means of the log-rank test. To test whether variables differed across groups, the χ 2 test or Fisher's exact test was used according to test condition. A Cox proportional hazards model including age, sex, WHO grade, histology, extent of tumor resection, Karnofsky performance status (KPS) score, and RPA groups was done to establish independent factor(s) for survival. Statistical significance was defined as P < All of the tests are two-sided. Statistical analysis was done using the SPSS software package, version 16.0 (SPSS, Inc.). An RPA (16) was done to test how histone modifications might influence prognosis as previously described (13). Briefly, a classification tree is constructed to the procedure for categorizing samples based on a series of sequential decisions. The whole data set served as the root of the classification tree. At each stage, a single predictor is used to split remaining samples into two nodes. The most well-known prognostic factor (for glioma, which is WHO grade) was firstly used as predefined split points to divide the cohort, followed by histology, which is another well-accepted prognostic factor, and then the histone modifications were applied as predictors to split Cancer Epidemiol Biomarkers Prev; 19(11) November
3 Liu et al. Table 1. Clinical characteristics of study sample WHO grade n Sex (M/F) Histology/ WHO grade n Median age (y) KPS ( 80/<80) /4 A/ (17-38) 7/ /40 A/ (14-74) 54/18 5/5 OA/ (14-51) 8/2 O/ (28-44) 10/ /21 AA/ (18-71) 24/18 AOA/ (21-68) 6/0 AO/ (30-37) 4/ /38 pgbm/ (18-72) 25/21 sgbm/ (22-68) 19/9 (Continued on the following page) remaining samples into additional nodes. The cutoff value is selected to maximize the likelihood ratio χ 2 statistic for the test so as to make samples above and below the cutoff value as different as possible with respect to classification. The cutoff values were calculated by a SAS program, which could run continuous likelihood ratio χ 2 tests until the most significant P value (which is the equivalent of the largest χ 2 statistic) occurred, when the patients' survival of the two nodes reached the maximal difference (confirmed by continuous log-rank tests). In the current study, when histone modifications were applied as predictors, all seven histone modifications and the expression level (from 0% to 100%) of them were substituted in the SAS program to determine the most significant one and its expression level. This splitting procedure continues until the data in each node are sufficiently well discriminated (which means when applying further continuous likelihood ratio χ 2 tests, a P < 0.05 could never be achieved) or until there are too few data in any node to support additional analysis. The RPA was carried out by the SAS software package, version 9.0 (SAS Institute, Inc.). Results Immunohistochemical study of H3K4diMe, H4R3monoMe, H4K20triMe, H3K9Ac, H3K18Ac, H4K12Ac, and H4K16Ac There were 230 patients who met the inclusion criteria and thus were included in this study. Major clinical and biological characteristics of these patients are summarized in Table 1. The expressions of H3K4diMe, H4R3- monome, H4K20triMe, H3K9Ac, H3K18Ac, H4K12Ac, and H4K16Ac in gliomas were nuclear rather than diffuse, sometimes with a low level of heterogeneity (Fig. 1A-G). The number of tumor cells stained positive by anti-h3k4dime, anti-h4r3monome, anti-h4k20trime, anti-h3k9ac, anti-h3k18ac, anti-h4k12ac, and anti- H4K16Ac ranged from 0% to 100% (mean, 60%, 61%, 70%, 70%, 76%, 62%, and 64%, respectively; Fig. 1H-N). The overall median expression of H3K4diMe, H4R3- monome, H4K20triMe, H3K9Ac, H3K18Ac, H4K12Ac, and H4K16Ac was 63%, 60%, 75%, 74%, 78%, 65%, and 68%, respectively. For each single tumor sample, the changes in expressions of H3K4diMe, H4R3monoMe, H3K9Ac, H3K18Ac, H4K12Ac, and H4K16Ac were all correlated with each other (Pearson's correlation coefficient, r ranged from to 0.528; P 0.028), with the exception of H4K20triMe when compared respectively with the former six modifications. H3K4diMe staining (Spearman's correlation coefficient, r = 0.328; P = ), H4R3monoMe (r = 0.193; P = 0.039), H3K9Ac (r = 0.200; P = 0.032), and H4K12Ac (r = 0.314; P = ) had low positive correlations with increasing WHO grades. No additional significant relationship was observed between the modifications and patient clinical characteristics. Global histone modification patterns and survival The median follow-up was 22.1 months. In the panel of 230 patients, 138 patients were dead at the time of this analysis, and 92 were alive, including 17 patients alive with tumor recurrence. The median OS and PFS of the whole population were 21.9 months (95% CI, months) and 19.4 months (95% CI, months), respectively. The survival data of different WHO grades and histologies are summarized in Table 1. RPA classified patients into 10 distinct prognostic groups (Fig. 2; Table 2). The first prognostic node was based on tumor grade, with those with low-grade glioma (WHO grades 1 and 2) having a longer survival than those with high-grade glioma (WHO grades 3 and 4). Patients with low-grade glioma were divided into two additional prognostic groups based on histology. Lowgrade glioma patients with oligodendroglioma or oligoastrocytoma had a better prognosis than those with astrocytoma. No other variable could segregate patients with oligodendroglioma or oligoastrocytoma (group 1). In contrast, patients with astrocytoma were classified into two separate groups by a third node based on acetylation 2890 Cancer Epidemiol Biomarkers Prev; 19(11) November 2010 Cancer Epidemiology, Biomarkers & Prevention
4 Histone Modifications Predict Glioma Prognosis Table 1. Clinical characteristics of study sample (Cont'd) Extent of tumor resection (total/subtotal/partial) Median PFS (mo) No tumor regrowth Median OS (mo) Alive at LO 4/0/ ( ) 6/ ( ) 6/10 56/8/ ( ) 44/ ( ) 50/72 8/2/ ( ) 10/ ( ) 10/10 10/0/ ( ) 10/ ( ) 10/12 27/6/ ( ) 16/ ( ) 6/42* 5/1/ ( ) 4/ ( ) 4/6 4/0/ ( ) 4/ ( ) 2/4 29/15/2 9.3 ( ) 12/ ( ) 2/46 21/1/6 6.9 ( ) 12/ ( ) 2/28* Abbreviations:M,male;F,female;LO,lastobservation;A,astrocytoma;OA,oligoastrocytoma;O,oligodendroglioma;AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma; pgbm, primary glioblastoma; sgbm, secondary glioblastoma. *Death of one patient not tumor related. of H3K9. Patients whose tumors expressed H3K9Ac in <88% of tumor cells (group 3) had a worse survival compared with patients whose tumors had at least 88% of cells expressing H3K9Ac (group 2). Patients with high-grade glioma were further divided into WHO grade 3 and 4 groups by a second node of WHOgrade.WithinWHOgrade3patients,RPAprovided a third node on the basis of histology. Again, patients with oligodendrocytic components (anaplastic oligodendroglioma and anaplastic oligoastrocytoma), which had a better prognosis, could not be segregated (group 4), whereas patients with anaplastic astrocytoma were split into two groups by a fourth node based on dimethylation of H3K4. Patients whose tumors expressed H3K4diMe in <64% of tumor cells (group 6) had a worse survival compared with patients whose tumors had at least 64% of cells expressing H3K4diMe (group 5). RPA also provided WHO grade 4 patients with a third node, which divided them into primary and secondary glioblastoma groups, with the former having a better prognosis. Furthermore, RPA incorporated histone modifications as a fourth node for WHO grade 4 patients. Acetylation of H3K18 significantly influenced survival of primary glioblastoma patients, with a greater survival for patients whose tumor expressed lower levels (<74% of tumor cells) of H3K18Ac (group 7 versus group 8). Meanwhile, trimethylation of H4K20 significantly influenced survival of secondary glioblastoma patients, with a greater survival for patients whose tumor expressed higher levels ( 75% of tumor cells) of H4K20triMe (group 9 versus group 10). The 10 groups defined the terminal classification of the 230 patients and were associated with significant different PFS (P < ) and OS (P < ; Table 2; Fig. 3). Cox proportional hazards models including age, sex, WHO grade, histology, extent of tumor resection, KPS, and RPA groups were analyzed to evaluate independent factors for OS and PFS, respectively. Sex, WHO grade, histology, extent of tumor resection, and KPS were not retained by the model. Conversely, age and RPA groups were found to influence OS significantly and independently. For PFS, age was no longer retained, with RPA groups being the only independent prognostic factor (Table 3). Discussion An altered pattern of epigenetic modifications is central to many common human diseases, including cancer (7,9,11).Epigeneticmodificationsmayaffectseveral steps of tumor cell biology, and may have a prognostic value in several cancer patients such as prostate cancer, breast cancer, and leukemia (17). Glioma tumor tissues typically contain both neoplastic and stromal tissues, which lead to their histologic heterogeneity and thus the discrepancies between pathologic grades and clinical outcomes. Genetic and epigenetic studies potentially allow for better classification of these tumors and separation of the tumors into different prognostic groups. The contribution of epigenetic changes to glioma carcinogenesis has been broadly studied in terms of aberrant promoter methylation induced gene silencing (9, 11, 18). Besides glioma, aberrant DNA methylation has been investigated in carcinogenesis and cancer development in various types of solid cancers and hematologic malignancies, and the potential targeting of DNA methylation as a therapeutic approach for cancer treatment is being evaluated (7, 9, 11). In comparison with DNA methylation, other mechanisms of epigenetic regulation, such as multiple modifications of histones, are less well characterized, especially for clinical purposes. Seligson et al. (12) first reported the global pattern of histone modifications, which may serve as predictors of clinical outcome that lower levels Cancer Epidemiol Biomarkers Prev; 19(11) November
5 Liu et al. Figure 1. Immunohistochemical analysis of glioma samples. Representative examples of positively stained sections (original magnification, 40) for H3K4diMe (A), H4R3monoMe (B), H4K20triMe (C), H3K9Ac (D), H3K18Ac (E), H4K12Ac (F), and H4K16Ac (G) from different patients. Distribution of staining for H3K4diMe (H), H4R3monoMe (I), H4K20triMe (J), H3K9Ac (K), H3K18Ac (L), H4K12Ac (M), and H4K16Ac (N) antibodies across all the 230 tumor samples. The Y axis represents the number of samples showing positive staining for the indicated percentage of cells stained (X axis), scored under high-powered field Cancer Epidemiol Biomarkers Prev; 19(11) November 2010 Cancer Epidemiology, Biomarkers & Prevention
6 Histone Modifications Predict Glioma Prognosis Figure 2. RPA results individualizing 10 different prognostic groups among the 230 samples from glioma patients who underwent resection included in our study. Each node, where the branches of the RPA tree bifurcate, divides patients according to whether the value of a specific feature (predictor) is above or below a selected cutoff value. The first node is represented by the tumor grade. In low-grade glioma patients, histologic subtype provides the second node, and histone modifications (e.g., the percentage of cells stained positively for H3K9Ac) provide the third node. High-grade glioma patients were further divided into WHO grade 3 and 4 ones. Histologic subtype and pathogenesis provide the third node, respectively, and histone modifications of H3K4diMe, H3K18Ac, or H4K20triMe provide the fourth node. of H3K18Ac, H3K9Ac, H3K4diMe, H4K12Ac, and H4R3diMe predicted higher risk of recurrence in prostate cancer patients by an unsupervised Random Forest clustering. Later on, Barlesi et al. (13) used RPA to classify resected non small cell lung cancer patients into seven distinct prognostic groups, which were marked with different tumor-node-metastasis stage, histology, and global histone modification patterns. Park et al. (14) further showed that some specific modifications could be predictors for the risk of recurrence and prognosis in Table 2. Median PFS and OS of the different groups of glioma patients established by RPA Group n Median PFS, mo (95% CI)* Median OS, mo (95% CI)* ( ) 52.4 ( ) ( ) 57.6 ( ) ( ) 32.0 ( ) ( ) 28.5 ( ) ( ) 18.6 ( ) ( ) 11.3 ( ) ( ) 14 ( ) ( ) 10.1 ( ) ( ) 9.7 ( ) ( ) 6.5 ( ) *P < Mean survival. Cancer Epidemiol Biomarkers Prev; 19(11) November
7 Liu et al. Figure 3. PFS (A) and (B) OS of the 10 different groups of glioma patients who underwent resection established by RPA. gastric adenocarcinoma patients. In our study, the pattern of expression and biological relevance of several histone modifications were analyzed for the first time in glioma patients who had undergone resection. To assess the potential prognostic use of histone modification profiles in a more widespread manner, we evaluated five modifications of H3K9Ac, H3K18Ac, H3K4diMe, H4K12Ac, and H4R3monoMe almost the same as in Seligson et al.'s study (12), and modifications of H4K16Ac and H4K20triMe, which are the two most common histone modification changes in human neoplasia (9, 15). The results suggested that histone H3K4diMe, H4K20triMe, H3K9Ac, and H3K18Ac may have an effect on OS and PFS of glioma patients, implying that more attention should be paid to epigenetic modifications in glioma carcinogenesis, especially global histone modification patterns. However, in comparison with previous reports that found that lower levels of H3K18Ac in prostate, lung, kidney, and breast cancer patients predict poor survival (12, 19, 20), we had reached an opposite finding that lower levels of H3K18Ac in glioblastoma patients predict better survival, which is in accordance with Tzao et al.'s results in esophageal carcinoma patients (21). This interesting phenomenon indicated that even if the same histone modification profiles could predict opposite prognosis in different cancer types, and that histone modification patterns may possess a tissue- and/or time-specific feature of heterogeneity. In addition, histone modifications are posttranslational covalent modifications (22); therefore, like most previous studies evaluating histone modifications, we had only detected the expressions of the modifications in protein level by immunohistochemistry but had not checked the expressions of the specific histones that were modified in mrna level, nor the relationship between immunohistochemical expression and mrna expression. This should be improved in future studies because the mrna level regulation may play an important role in influencing both the quantity and function of the histones that would be modified posttranslationally. There are several methodologies to investigate the potential prognostic value of clinical and biological features, and we chose RPA for the same reasons indicated by Barlesi et al. (13), that RPA is suitable for analyzing variables intricately connected and that the procedure of RPA is concise and the result is easy to follow (23, 24). The validity of this method is supported by using WHO grade, a well-known prognostic factor in glioma patients, as the first node. Therefore, the histone modifications retained by RPA could be regarded as potentially valuable prognostic factors. However, how the expression of particular genes or tumor behavior is modulated by specific epigenetic alterations or combination of alterations remains unclear. One emerging model, called histone code hypothesis, assumes that specific combinations of histone modifications may confer the overall expression status of a region of chromatin (22), which should be further investigated in tumors characterized by different patterns of histone modifications. Additionally, one limitation of the RPA method is that it requires a single predictor at each node for splitting; therefore, the combination of two or more histone modifications could not severed as a predictor in the RPA procedure. However, as indicated in the results, several histone modifications were correlated, and in the current study, only the most significant ones were retained by RPA. In the future studies, more statistical strategies can be applied because that summation of the individual histone modifications may predict survival better than individual markers. Our efforts to identify multiple histone modifications in the tumors may not only provide additional prognostic information but also contribute to clinical decisions after further verification. Management decisions, such as timing of intervention, extent of surgical resection, 2894 Cancer Epidemiol Biomarkers Prev; 19(11) November 2010 Cancer Epidemiology, Biomarkers & Prevention
8 Histone Modifications Predict Glioma Prognosis timing and dose of radiotherapy, and long-term benefits versus risks of chemotherapy, have been controversial about the optimal therapy in gliomas (4, 5). Although WHO grade is the most important prognostic factor for glioma patients, the broad differences of treatment response and survival within grades suggest that the aggressiveness of treatment may not be decided simply by grade. Based on our results, histone modifications may be considered in the attempt to better define prognostic subgroups by further validation. An interesting observation that RPA group 7 (belongs to WHO grade 4) had a better survival than group 6 (WHO 3) had further highlighted the discrepancies within WHO grading, which has been noticed by many neuro-oncologists. For those with worse prognosis as indicated by epigenetic profiles, more aggressive adjuvant therapy could be considered. About chemotherapy, to date, the strongest evidence that epigenetic alterations can predict responses to therapy is provided by the methylation-associated silencing of the DNA repair protein MGMT in glioma. MGMT hypermethylation is the best independent predictor of glioma patients' response to alkylating agents (25), including temozolomide (26). Intriguingly, several drugs interacting with histone modifications have been developed in recent years, such as the histone deacetylase inhibitors (27). Several structurally distinct classes of histone deacetylase inhibitors have been developed and tested (28), of which a significant anticancer activity as well as good toleration were reported in several cancer types including glioma (29). The imbalance of histone acetylation in cancer cells provides an experimental basis for these treatments (12, 15), which suggests that the global histone modification patterns, when characterized in more detail, might provide insights into the specificity of these drugs. For instance, the loss of monoacetylated H4K16 can be reversed by a new class of drugs that inhibit sirtuins (30), the specific subclass of histone deacetylase inhibitors that deacetylate H4K16. Numerous additional studies are still ongoing and results are awaited. Based on the existing results (25, 26) including ours, we suggest that histone modifications should be further investigated in combination with DNA methylation as predictors of response to chemotherapy in the future, which may better help to select the most appropriate therapies on the basis of epigenetic profiles of tumors. Moreover, when evaluating new prognostic biomarkers in future studies, those well-accepted biomarkers, such as MGMT for glioblastoma and 1p19q for oligodendroglial tumors, should be incorporated to help validating the results. The detection of tumor molecular signatures in body fluids has implications for the identification of patients with high-risk or preinvasive/early-stage lesions and for monitoring residual disease. Aberrant DNA methylation has been studied in body fluids such as plasma/ serum, urine, sputum, bronchoalveolar lavage fluid, and ductal lavage fluid (11), whereas histone modifications have never been tested in body fluids yet. To this end, Table 3. Cox proportional hazards regressions for PFS and OS Variable PFS OS HR (95% CI) P HR (95% CI) P Group 1 Reference Reference ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) < ( ) < ( ) < ( ) ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < ( ) < Sex: male vs female 0.88 ( ) ( ) Age 50 y 1.29 ( ) ( ) Extent of resection Total resection Reference Reference Subtotal resection 1.32 ( ) ( ) Partial resection 0.96 ( ) ( ) KPS < ( ) ( ) NOTE: Pathology and WHO grade were not retained by the model because of colinearity with RPA group variable (linearly dependent covariables). Cancer Epidemiol Biomarkers Prev; 19(11) November
9 Liu et al. we are planning to do a prospective study on epigenetic alteration status including gene promoter methylation and histone modification in a longitudinal way. In conclusion, our results highlight the prognostic value of epigenetic changes involving multiple histone modifications in glioma, which may help in identifying glioma patients with different prognosis and selecting patients for optimal adjuvant treatments. In addition, our observations provide a rationale to modify chemotherapy with drugs interacting with histone modifications, such as histone deacetylase inhibitors. Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. Received 04/29/2010; revised 08/03/2010; accepted 08/05/2010; published OnlineFirst 09/14/2010. References 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, CA Cancer J Clin 2006;56: Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009; 472: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization classification of tumours of the central nervous system. Lyon: IARC Press; Duran I, Raizer JJ. Low-grade gliomas: management issues. Expert Rev Anticancer Ther 2007;7:S Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: Schiff D, Brown PD, Giannini C. Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007;69: Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18: Holliday R. The inheritance of epigenetic defects. Science 1987;238: Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8: Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349: Esteller M. Epigenetics in cancer. N Engl J Med 2008;358: Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al. Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 2007;25: Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15: Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37: Zhang HP, Singer B. Partitioning in the Health Sciences. New York: Springer; Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3: Martinez R, Schackert G. Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment. Epigenetics 2007;2: Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174: Elsheikh SE, Green AR, Rakha EA, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 2009;69: Tzao C, Tung HJ, Jin JS, et al. Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 2009;22: Wang Y, Fischle W, Cheung W, Jacobs S, Khorasanizadeh S, Allis CD. Beyond the double helix: writing and reading the histone code. Novartis Found Symp 2004;259:3 17; discussion 17 21, Young SS, Ge N. Recursive partitioning analysis of complex disease pharmacogenetic studies. I. Motivation and overview. Pharmacogenomics 2005;6: Zaykin DV, Young SS. Large recursive partitioning analysis of complex disease pharmacogenetic studies. II. Statistical considerations. Pharmacogenomics 2005;6: Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343: Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352: Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 2004;10: Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004;3: Lukas RV, Boire A, Nicholas MK. Emerging therapies for malignant glioma. Expert Rev Anticancer Ther 2007;7:S Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e Cancer Epidemiol Biomarkers Prev; 19(11) November 2010 Cancer Epidemiology, Biomarkers & Prevention
10 Global Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients Bo-lin Liu, Jin-xiang Cheng, Xiang Zhang, et al. Cancer Epidemiol Biomarkers Prev 2010;19: Published OnlineFirst September 14, Updated version Access the most recent version of this article at: doi: / epi Cited articles Citing articles This article cites 28 articles, 6 of which you can access for free at: This article has been cited by 1 HighWire-hosted articles. Access the articles at: alerts Sign up to receive free -alerts related to this article or journal. Reprints and Subscriptions Permissions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. To request permission to re-use all or part of this article, use this link Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.
J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 5 NUMBER 8 OCTOBER 7 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Global Histone Modifications Predict Prognosis of Resected Non Small-Cell Lung Cancer Fabrice Barlési, Giuseppe Giaccone,
More informationThe Global Histone Modification Patterns of Osteosarcoma
The Korean Journal of Pathology 2011; 45: 146-150 DOI: 10.4132/KoreanJPathol.2011.45.2.146 The Global Histone Modification Patterns of Osteosarcoma Sung-Im Do Sung-Jig Lim 1 Youn-Wha Kim Liliana G. Olvi
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More information5-hydroxymethylcytosine loss is associated with poor prognosis for
5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas Feng Zhang 1,*, Yifan Liu 2, Zhiwen Zhang 1, Jie Li 1, Yi Wan 3, Liying Zhang 1, Yangmei
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationCancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006
Chinese Journal of Cancer Original Article Cancer incidence and patient survival rates among the residents in the Pudong New Area of Shanghai between 2002 and 2006 Xiao-Pan Li 1, Guang-Wen Cao 2, Qiao
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationExamining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.
Stratified Medicine Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to. Looking in detail at cancer cells and their genetic make up. Permit
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationThe 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis
The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics
More informationGenetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma
Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma M.J. Wang, Y. Zhu, X.J. Guo and Z.Z. Tian Department of Orthopaedics, Xinxiang Central Hospital, Xinxiang,
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationAssociation between downexpression of mir-1301 and poor prognosis in patients with glioma
European Review for Medical and Pharmacological Sciences 2017; 21: 4298-4303 Association between downexpression of mir-1301 and poor prognosis in patients with glioma Q.-L. BAI, C.-W. HU, X.-R. WANG, G.-F.
More informationTechnology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2018. All rights reserved.
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationHigh Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10621 RESEARCH ARTICLE High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas Yao-Wu Wang 1, Chun-Li Yin 2, Hong-Yi Zhang
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 19 CH-857 Zurich http://www.zora.uzh.ch Year: 29 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationCarmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationAberrant DNA methylation of MGMT and hmlh1 genes in prediction of gastric cancer
Aberrant DNA methylation of MGMT and hmlh1 genes in prediction of gastric cancer J. Jin 1,2, L. Xie 2, C.H. Xie 1 and Y.F. Zhou 1 1 Department of Radiation & Medical Oncology, Zhongnan Hospital of Wuhan
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationTitle: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen
Author's response to reviews Title: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen Authors: Caiyun Liu (liucaiyun23@yahoo.com.cn) Bin Dong
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationEpidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis
Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis G. Pesce 1, A. Bordoni, F. Montanaro, R. Renella 3, A. Richetti 1, D. Boscherini 3, S. Mauri 4,
More informationInterferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas
MOLECULAR AND CLINICAL ONCOLOGY 3: 909-913, 2015 Interferon β and temozolomide combination therapy for temozolomide monotherapy refractory malignant gliomas HIROSHI KAWAJI, TSUTOMU TOKUYAMA, TOMOHIRO YAMASAKI,
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationIDH1 R132H/ATRX Immunohistochemical validation
IDH1 R132H/ATRX Immunohistochemical validation CIQC/DSM 2016 12 June 2016 0835-0905 Stephen Yip, M.D., Ph.D., FRCPC University of British Columbia Disclosure Statement I have nothing to disclose I will
More informationInvestigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma
Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma Q. Zhang 1, L.Y. Lv 1, B.J. Li 1, J. Zhang 1 and F. Wei 2 1 Department of Orthopaedics,
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationDetection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
DOI.7/s4--3-7 ORIGINAL ARTICLE Detection of IDH mutation in human gliomas: comparison of immunohistochemistry and sequencing Shingo Takano Wei Tian Masahide Matsuda Tetsuya Yamamoto Eiichi Ishikawa Mika
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationAnalysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix
DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department
More informationAssociation of mir-21 with esophageal cancer prognosis: a meta-analysis
Association of mir-21 with esophageal cancer prognosis: a meta-analysis S.-W. Wen 1, Y.-F. Zhang 1, Y. Li 1, Z.-X. Liu 2, H.-L. Lv 1, Z.-H. Li 1, Y.-Z. Xu 1, Y.-G. Zhu 1 and Z.-Q. Tian 1 1 Department of
More informationBevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma
Original Article Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Lin-Bo Cai, Juan Li, Ming-Yao Lai, Chang-Guo Shan, Zong-De Lian, Wei-Ping Hong, Jun-Jie Zhen,
More informationA study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric cancer.
Biomedical Research 2018; 29 (2): 365-370 ISSN 0970-938X www.biomedres.info A study on clinicopathological features and prognostic factors of patients with upper gastric cancer and middle and lower gastric
More informationMOLECULAR DIAGNOSTICS OF GLIOMAS
MOLECULAR DIAGNOSTICS OF GLIOMAS Arie Perry, M.D. Director, Neuropathology Division DIFFUSE GLIOMAS Cell types Astrocytomas (A) Oligodendrogliomas (O) Mixed oligoastrocytoma (MOA) Three WHO grades: II,
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationHigh Expression of H3K9me3 Is a Strong Predictor of Poor Survival in Patients With Salivary Adenoid Cystic Carcinoma
High Expression of H3K9me3 Is a Strong Predictor of Poor Survival in Patients With Salivary Adenoid Cystic Carcinoma Ronghui Xia, DDS; Rongrui Zhou, DDS, MDS; Zhen Tian, DDS, MDS, PhD; Chunye Zhang, DDS,
More informationCase Presentation: USCAP Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center
Case Presentation: USCAP 2016 Jason T. Huse, MD, PhD Assistant Member Department of Pathology Memorial Sloan Kettering Cancer Center Case History 53 year old female with a long standing history of migraines
More informationPrognostic Significance of Overexpression of EZH2 and H3k27me3 Proteins in Gastric Cancer
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.7.3173 Prognostic Significance of Overexpression of EZH2 and H3k27me3 Proteins in Gastric Cancer RESEARCH COMMUNICATION Prognostic Significance of Overexpression
More informationExpression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 5525-5530 Expression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer Y.-X. SHI, B.-L. YE, B.-R. HU, X.-J.
More informationMorphological features and genetic alterations
Morphological features and genetic alterations Tutor : Audrey Rousseau Caget Lise: Université d Angers Iorio Vittoria: Seconda Università degli studi di Napoli Manaila Roxana: Iuliu Hatieganu University
More informationConcurrent Analysis of Human Equilibrative Nucleoside Transporter 1 and Ribonucleotide
1 ORIGINAL ARTICLE Concurrent Analysis of Human Equilibrative Nucleoside Transporter 1 and Ribonucleotide Reductase Subunit 1 Expression Increases Predictive Value for Prognosis in Cholangiocarcinoma Patients
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationSUPPLEMENTARY FIGURES: Supplementary Figure 1
SUPPLEMENTARY FIGURES: Supplementary Figure 1 Supplementary Figure 1. Glioblastoma 5hmC quantified by paired BS and oxbs treated DNA hybridized to Infinium DNA methylation arrays. Workflow depicts analytic
More informationInfluence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma
Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma Z.F. Liu, A.L.J. Asila, K. Aikenmu, J. Zhao, Q.C. Meng and R. Fang Department of Orthopaedics, Chinese Medicine Hospital of
More informationPrognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous Cell Carcinoma in China
1663 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(12): 1663-1667. doi: 10.7150/jca.15216 Prognostic Value of Plasma D-dimer in Patients with Resectable Esophageal Squamous
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationPrognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status.
Prognostic value of ADC in glioblastoma multiforme and its correlation with survival and MGMT promoter methylation status. R. Zalazar, M.D. Hernández, M. Páramo, P. Slon, M. Millor Muruzabal, J. Solorzano
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationSupplementary Online Content
Supplementary Online Content Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG Oncology
More informationAnalysis of the outcome of young age tongue squamous cell carcinoma
Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of
More informationZurich Open Repository and Archive. Long-term survival of glioblastoma patients treated with radiotherapy and lomustine plus temozolomide
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2009 Long-term survival of glioblastoma patients treated with radiotherapy and lomustine
More informationCpG Island Methylator Phenotype in Primary Gastric Carcinoma
Showa Univ J Med Sci 25 2, 127 132, June 2013 Original CpG Island Methylator Phenotype in Primary Gastric Carcinoma Masayuki TOJO 1, Kazuo KONISHI 1, Yuichiro YANO 1, Atsushi KATAGIRI 1, Hisako NOZAWA
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bredel M, Scholtens DM, Yadav AK, et al. NFKBIA deletion in
More informationBIOSTATISTICAL METHODS AND RESEARCH DESIGNS. Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
BIOSTATISTICAL METHODS AND RESEARCH DESIGNS Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA Keywords: Case-control study, Cohort study, Cross-Sectional Study, Generalized
More informationThe association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
Wang et al. Journal of Ovarian Research (2016) 9:23 DOI 10.1186/s13048-016-0231-1 RESEARCH The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More information290 Clin Oncol Cancer Res (2009) 6: DOI /s
290 Clin Oncol Cancer Res (2009) 6: 290-295 DOI 10.1007/s11805-009-0290-9 Analysis of Prognostic Factors of Esophageal and Gastric Cardiac Carcinoma Patients after Radical Surgery Using Cox Proportional
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationReviews in Clinical Medicine
Mashhad University of Medical Sciences (MUMS) Reviews in Clinical Medicine Clinical Research Development Center Ghaem Hospital Prognostic value of HER2/neu expression in patients with prostate cancer:
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationDISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
More informationA clinical perspective on neuropathology and molecular genetics in brain tumors
A clinical perspective on neuropathology and molecular genetics in brain tumors M.J. van den Bent Erasmus MC Cancer Institute Rotterdam, the Netherlands Disclosures Member speakersbureau: MSD Consultancy:
More informationRESEARCH COMMUNICATION
DOI:http://dx.doi.org/10.7314/APJCP.2012.13.1.199 RESEARCH COMMUNICATION Prognostic Significance of CYFRA21-1, CEA and Hemoglobin in Patients with Esophageal Squamous Cancer Undergoing Concurrent Chemoradiotherapy
More informationTitle:DNA Methylation Subgroups and the CpG Island Methylator Phenotype in Gastric Cancer: A Comprehensive Profiling Approach
Author's response to reviews Title:DNA Methylation Subgroups and the CpG Island Methylator Phenotype in Gastric Cancer: A Comprehensive Profiling Approach Authors: Marie Loh (m.loh@imperial.ac.uk) Natalia
More informationExploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies
Exploitation of Epigenetic Changes to Distinguish Benign from Malignant Prostate Biopsies Disclosures MDxHealth Scientific Advisor 2 Case Study 54-year-old man referred for a PSA of 7 - Healthy, minimal
More informationThe New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas
The New WHO Classification and the Role of Integrated Molecular Profiling in the Diagnosis of Malignant Gliomas Stefan Prokop, MD Neuropathology Fellow Hospital of the University of Pennsylvania Background
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationThe prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study
Received: 21 September 2017 Accepted: 22 January 2018 DOI: 10.1002/pros.23492 ORIGINAL ARTICLE The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective
More informationLong non-coding RNA TUSC7 expression is independently predictive of outcome in glioma
European Review for Medical and Pharmacological Sciences 2017; 21: 3605-3610 Long non-coding RNA TUSC7 expression is independently predictive of outcome in glioma X.-L. MA 1, W.-D. ZHU 2, L.-X. TIAN 2,
More informationClinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy
Yang et al. World Journal of Surgical Oncology (2018) 16:51 https://doi.org/10.1186/s12957-018-1332-7 RESEARCH Open Access Clinical significance and prognostic value of receptor conversion in hormone receptor
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More information